Moderna jumps as FDA flu-shot approval reinforces recent business momentum

Moderna (MRNA) is up 10.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is the FDA approval of Moderna’s mFLUSIVA seasonal influenza vaccine, a major regulatory win that gives the company its first approved flu shot and expands its commercial respiratory portfolio. The move may also be getting support from the company’s recent second-quarter update, which showed a narrower quarterly loss and kept investors focused on additional late-stage pipeline catalysts.

Details:

Moderna announced that the FDA approved mFLUSIVA, its mRNA-based seasonal flu vaccine, giving the company a new marketed product ahead of the 2026 to 2027 flu season.

The approval followed a late-stage study in adults 50 and older that showed fewer influenza cases versus a standard flu shot comparator, helping validate the product after earlier regulatory setbacks.

In its July 31 second-quarter release, the company reported a smaller loss per share than a year earlier and said it expects roughly 55% of second-half 2026 revenue to be recognized in the third quarter.

This could also be because investors are reassessing Moderna’s broader platform value as regulatory progress in flu adds to its existing COVID and RSV franchises and supports future combination-vaccine plans.

Sources:

Moderna, FDA, AP News

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRNA Insider Trading Activity

$MRNA insiders have traded $MRNA stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:

STEPHANE BANCEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 499,246 shares for an estimated $28,715,011.
STEPHEN HOGE (President) has made 0 purchases and 4 sales selling 320,017 shares for an estimated $16,741,685.
SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 17,356 shares for an estimated $899,596.
NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MRNA Hedge Fund Activity

We have seen 355 institutional investors add shares of $MRNA stock to their portfolio, and 326 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 17,626,713 shares (+62.9%) to their portfolio in Q1 2026, for an estimated $848,197,429
CAPITAL WORLD INVESTORS added 5,869,654 shares (+45.8%) to their portfolio in Q1 2026, for an estimated $282,447,750
GOLDMAN SACHS GROUP INC added 2,653,078 shares (+67.2%) to their portfolio in Q1 2026, for an estimated $127,666,113
BAILLIE GIFFORD & CO removed 2,373,736 shares (-11.5%) from their portfolio in Q2 2026, for an estimated $166,232,732
WELLINGTON MANAGEMENT GROUP LLP added 2,274,302 shares (+2730.4%) to their portfolio in Q1 2026, for an estimated $109,439,412
TWO SIGMA INVESTMENTS, LP added 1,744,308 shares (+23.8%) to their portfolio in Q1 2026, for an estimated $83,936,100
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 1,560,559 shares (-96.6%) from their portfolio in Q1 2026, for an estimated $75,094,099

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MRNA Analyst Ratings

Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 02/23/2026

To track analyst ratings and price targets for $MRNA, check out Quiver Quantitative's $MRNA forecast page.

$MRNA Price Targets

Multiple analysts have issued price targets for $MRNA recently. We have seen 8 analysts offer price targets for $MRNA in the last 6 months, with a median target of $46.5.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $39.0 on 07/08/2026
Luca Issi from RBC Capital set a target price of $45.0 on 07/07/2026
Dimple Gosai from B of A Securities set a target price of $38.0 on 07/07/2026
Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026
Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
Eliana Merle from UBS set a target price of $45.0 on 05/04/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.